Cargando…

Effect of denosumab on bone mineral density and biochemical markers of bone turnover: 8-year results of a phase 2 clinical trial

SUMMARY: In a phase 2 study, continued denosumab treatment for up to 8 years was associated with continued gains in bone mineral density and persistent reductions in bone turnover markers. Denosumab treatment was well tolerated throughout the 8-year study. INTRODUCTION: The purpose of this study is...

Descripción completa

Detalles Bibliográficos
Autores principales:	McClung, M. R., Lewiecki, E. M., Geller, M. L., Bolognese, M. A., Peacock, M., Weinstein, R. L., Ding, B., Rockabrand, E., Wagman, R. B., Miller, P. D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3536967/ https://www.ncbi.nlm.nih.gov/pubmed/22776860 http://dx.doi.org/10.1007/s00198-012-2052-4

Ejemplares similares

Observations following discontinuation of long-term denosumab therapy
por: McClung, M. R., et al.
Publicado: (2017)

Effect of Denosumab on Bone Mineral Density and Markers of Bone Turnover among Postmenopausal Women with Osteoporosis
por: Sánchez, A., et al.
Publicado: (2016)

Bone Mineral Density After Transitioning From Denosumab to Alendronate
por: Kendler, David, et al.
Publicado: (2019)

Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients
por: Kamimura, M., et al.
Publicado: (2016)

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures
por: Austin, Matthew, et al.
Publicado: (2012)

Relationship Between Bone Mineral Density T‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment
por: Ferrari, S, et al.
Publicado: (2019)

Denosumab for the treatment of osteoporosis
por: McClung, Michael R.
Publicado: (2017)

Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years
por: Ferrari, S., et al.
Publicado: (2015)

Effects of denosumab on bone mineral density and bone turnover markers in rheumatoid arthritis patients switching from bisphosphonates
por: Kaneko, Tetsuya, et al.
Publicado: (2019)

Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis
por: Hu, Mingwei, et al.
Publicado: (2023)

Association of bone mineral density with biochemical markers of bone turnover in hemodialysis children
por: Hajizadeh, Niloofar, et al.
Publicado: (2016)

A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab
por: McClung, M. R., et al.
Publicado: (2020)

Reduction of Cortical Bone Turnover and Erosion Depth After 2 and 3 Years of Denosumab: Iliac Bone Histomorphometry in the FREEDOM Trial
por: Chavassieux, Pascale, et al.
Publicado: (2019)

Effects of Long-Term Denosumab on Bone Histomorphometry and Mineralization in Women With Postmenopausal Osteoporosis
por: Dempster, David W, et al.
Publicado: (2018)

Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study
por: Dito, Giorgia, et al.
Publicado: (2023)

Bone turnover in elderly men: relationships to change in bone mineral density
por: Nguyen, Tuan V, et al.
Publicado: (2007)

Effects of Denosumab on Bone Metabolic Markers and Bone Mineral Density in Patients Treated with Glucocorticoids
por: Sawamura, Masato, et al.
Publicado: (2017)

A hospital based study of biochemical markers of bone turnovers & bone mineral density in north Indian women
por: Kumar, Ashok, et al.
Publicado: (2013)

Evaluation of bone mineral density and bone turnover in children on anticoagulation
por: Thom, Katharina, et al.
Publicado: (2023)

Influence of denosumab on bone mineral density in a severe case of pregnancy-associated osteoporosis
por: Stumpf, U., et al.
Publicado: (2021)

Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide
por: Blumsohn, A., et al.
Publicado: (2010)

Skeletal responses to romosozumab after 12 months of denosumab
por: McClung, Michael R., et al.
Publicado: (2021)

Bone turnover rate and bone formation/resorption balance during the early stage after switching from a bone resorption inhibitor to denosumab are predictive factors of bone mineral density change
por: Nakatoh, Shinichi
Publicado: (2017)

Pretreatment of daily teriparatide enhances the increase of bone mineral density in cortical bones by denosumab therapy
por: Kamimura, Mikio, et al.
Publicado: (2018)

Effects of E2/P4 oral capsules on bone turnover in women with vasomotor symptoms
por: McClung, Michael R., et al.
Publicado: (2022)

Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients on Suppressive Levothyroxine Therapy for Differentiated Thyroid Carcinoma
por: Kim, Chei Won, et al.
Publicado: (2015)

Bone turnover markers in serum but not in saliva correlate with bone mineral density
por: Kerschan-Schindl, Katharina, et al.
Publicado: (2020)

Bone Turnover Markers and Bone Mineral Density in Children with Hypophosphatemic Rickets
por: Michałus, Izabela, et al.
Publicado: (2022)

Updated trabecular bone score accounting for the soft tissue thickness (TBS(TT)) demonstrated significantly improved bone microstructure with denosumab in the FREEDOM TBS post hoc analysis
por: Hans, Didier, et al.
Publicado: (2022)

Effect of Denosumab on Bone Mineral Density of Hematopoietic Stem Cell Transplantation Recipients
por: Jeong, Chaiho, et al.
Publicado: (2020)

Efficacy and Safety of Denosumab in Osteoporosis or Low Bone Mineral Density Postmenopausal Women
por: Chen, Yi, et al.
Publicado: (2021)

Laboratory reproducibility of biochemical markers of bone turnover in clinical practice
por: Schafer, A. L., et al.
Publicado: (2009)

Comparative effects of denosumab or bisphosphonate treatment on bone mineral density and calcium metabolism in postmenopausal women
por: Augoulea, A., et al.
Publicado: (2017)

SAT-021 Effects of E2/P4 Oral Capsules on Bone Turnover in Women with Vasomotor Symptoms
por: Constantine, Ginger, et al.
Publicado: (2020)

Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness–adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension
por: Hans, Didier, et al.
Publicado: (2023)

Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab
por: Kendler, D.L., et al.
Publicado: (2019)

Bone turnover and bone mineral density in old persons with type 2 diabetes
por: Martins, João Martin, et al.
Publicado: (2018)

Effects of bone turnover status on the efficacy and safety of denosumab among haemodialysis patients
por: Hori, Mayuko, et al.
Publicado: (2022)

Effect of antiretroviral therapy on bone turnover and bone mineral density in men with primary HIV-1 infection
por: Vlot, Mariska C., et al.
Publicado: (2018)

Impact of severity, duration, and etiology of hyperthyroidism on bone turnover markers and bone mineral density in men
por: El Hadidy, El Hadidy M, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_kaaju5ej604djad7h103n9jheh